Yaskolka Meir, Anat
Keller, Maria
Hoffmann, Anne
Rinott, Ehud
Tsaban, Gal
Kaplan, Alon
Zelicha, Hila
Hagemann, Tobias
Ceglarek, Uta
Isermann, Berend
Shelef, Ilan
Blüher, Matthias
Stumvoll, Michael
Li, Jun
Haange, Sven-Bastian
Engelmann, Beatrice
Rolle-Kampczyk, Ulrike
von Bergen, Martin
Hu, Frank B.
Stampfer, Meir J.
Kovacs, Peter
Liang, Liming
Shai, Iris
Funding for this research was provided by:
DFG (209933838)
Ministry of Health, State of Israel (87472511)
Ministry of Science, Technology and Space (3-13604)
California Walnut Commission
Israel Council for Higher Education- Zuckerman
Universität Leipzig
Article History
Received: 18 May 2023
Accepted: 31 July 2023
First Online: 25 September 2023
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Medical Ethics Board and Institutional Review Board at Soroka University Medical Centre, Be’er Sheva, Israel (SOR-0280–16). Participants provided written informed consent and received no compensation.This trial was registered at ClinicalTrials.gov (NCT03020186). The research was conducted in strict compliance with the Helsinki Declaration.
: Not applicable.
: MB received honoraria as a consultant and speaker from Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Lilly, Novo Nordisk, Novartis, and Sanofi. All other authors declare that they have no competing interests.